EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access

Efficacy and Safety of Intravenous Tenecteplase Before Endovascular Thrombectomy for Acute Ischemic Stroke: The Multicenter, Randomized, BRIDGE‐TNK Trial Protocol

Zhongming Qiu iD, Fengli Li iD, Dongjing Xie, Guangxiong Yuan, Thanh N Nguyen iD, Kai Zhou iD, Raul G Nogueira iD, Jeffrey L Saver iD, Bruce C V Campbell iD, Gregory W Albers iD, Hongfei Sang iD, Linyu Li iD und 6 weitere

Journal of the American Heart Association · 2024

DOI: 10.1161/jaha.124.036765 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Zhongming Qiu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Xinqiao Hospital and The Second Affiliated Hospital Army Medical University (Third Military Medical University) Chongqing China. Hauptthemen laut MEDLINE: Endovascular Procedures, Fibrinolytic Agents, Ischemic Stroke, Tenecteplase. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Six randomized trials have not detected a difference between intravenous alteplase plus endovascular thrombectomy and endovascular thrombectomy alone in stroke. Tenecteplase, a recombinant human tenecteplase tissue‐type plasminogen activator, is a genetically modified variant of alteplase. It is unclear whether the outcomes are different if alteplase is replaced with tenecteplase. This trial aims to determine whether intravenous tenecteplase within 4.5 hours of time last known well confers benefit in patients with acute ischemic stroke with large‐vessel occlusion who undergo endovascular thrombectomy.

Methods

BRIDGE‐TNK (Thrombectomy With Versus Without rhTNK‐tPA in Stroke) is an investigator‐initiated, multicenter, prospective, randomized, open‐label trial with blinded end point evaluation conducted at 40 thrombectomy‐capable centers in China. This trial will randomize 544 patients with intravenous thrombolysis–eligible stroke (272 in each arm) with large‐vessel occlusion within 4.5 hours of last known well to receive bridging intravenous tenecteplase with endovascular thrombectomy (tenecteplase‐plus‐thrombectomy group) or endovascular thrombectomy alone (thrombectomy‐alone group). The primary outcome is the proportion of patients achieving functional independence, defined as a score of 0 to 2 on the modified Rankin Scale, at 90 days. Safety will be assessed via symptomatic intracranial hemorrhage at 48 hours and death at 90 days.

Conclusions

BRIDGE‐TNK will provide important data on the role of intravenous tenecteplase before endovascular thrombectomy in patients with acute ischemic stroke with large‐vessel occlusion who can be treated within 4.5 hours of last known well. Registration URL: https://clinicaltrials.gov . Unique identifier: NCT04733742.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endovascular ProceduresFibrinolytic AgentsIschemic StrokeTenecteplaseThrombectomyAdultAgedFemaleHumansMaleMiddle AgedAdministration, IntravenousChinaCombined Modality TherapyMulticenter Studies as TopicProspective StudiesRandomized Controlled Trials as TopicThrombolytic TherapyTime FactorsTissue Plasminogen ActivatorTreatment Outcome

Stichwörter der Autor:innen

acute ischemic strokeendovascular treatmentlarge‐vessel occlusionprotocolrandomized trialtenecteplase

Substanzen

Fibrinolytic AgentsTenecteplaseTissue Plasminogen Activator

Autor:innen und Institutionen

  • Xinqiao Hospital and The Second Affiliated Hospital Army Medical University (Third Military Medical University) Chongqing China.
  • Xiangtan Central Hospital Xiangtan China.
  • Boston Medical Center Boston MA.
  • UPMC Stroke Institute University of Pittsburgh School of Medicine Pittsburgh PA.
  • David Geffen School of Medicine at University of California at Los Angeles Los Angeles CA.
  • Melbourne Brain Centre at the Royal Melbourne Hospital University of Melbourne Parkville Vic Australia.

ORCID-Profile: Zhongming Qiu, Fengli Li, Thanh N Nguyen, Kai Zhou, Raul G Nogueira, Jeffrey L Saver, Bruce C V Campbell, Gregory W Albers, Hongfei Sang, Linyu Li, Duolao Wang, Wenjie Zi, Qingwu Yang

Zitieren

APA

Qiu, Z., Li, F., Xie, D., Yuan, G., Nguyen, T. N., Zhou, K., Nogueira, R. G., Saver, J. L., Campbell, B. C. V., Albers, G. W., Sang, H., Li, L., Tian, Y., Meng, Z., Wang, D., Zi, W., Yang, Q., & BRIDGE‐TNK investigators (2024). Efficacy and Safety of Intravenous Tenecteplase Before Endovascular Thrombectomy for Acute Ischemic Stroke: The Multicenter, Randomized, BRIDGE‐TNK Trial Protocol. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.036765

Vancouver

Qiu Z, Li F, Xie D, Yuan G, Nguyen TN, Zhou K, et al. Efficacy and Safety of Intravenous Tenecteplase Before Endovascular Thrombectomy for Acute Ischemic Stroke: The Multicenter, Randomized, BRIDGE‐TNK Trial Protocol. Journal of the American Heart Association. 2024. doi:10.1161/jaha.124.036765

BibTeX
@article{Qiu2024,
  author = {Qiu, Zhongming and Li, Fengli and Xie, Dongjing and Yuan, Guangxiong and Nguyen, Thanh N and Zhou, Kai and Nogueira, Raul G and Saver, Jeffrey L and Campbell, Bruce C V and Albers, Gregory W and Sang, Hongfei and Li, Linyu and Tian, Yan and Meng, Zhaoyou and Wang, Duolao and Zi, Wenjie and Yang, Qingwu and BRIDGE‐TNK investigators, BRIDGE‐TNK investigators},
  title = {Efficacy and Safety of Intravenous Tenecteplase Before Endovascular Thrombectomy for Acute Ischemic Stroke: The Multicenter, Randomized, BRIDGE‐TNK Trial Protocol},
  journal = {Journal of the American Heart Association},
  year = {2024},
  doi = {10.1161/jaha.124.036765}
}
Kostenlos starten →